Ocugen, Inc. Common Stock (OCGN)

Price$1.93

Favorite Metrics

Price vs S&P 500 (26W)4.95%

Price vs S&P 500 (4W)-20.67%

Market Capitalization$639.40M

All Metrics

Book Value / Share (Quarterly)$0.01

P/TBV (Annual)1.94x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)366.28%

Cash Flow / Share (Quarterly)$-0.18

Price vs S&P 500 (YTD)41.80%

Net Profit Margin (TTM)-1192.18%

EPS (TTM)$-0.22

10-Day Avg Trading Volume5.49M

EPS Excl Extra (TTM)$-0.22

EPS (Annual)$-0.23

ROI (Annual)-92.71%

Net Profit Margin (5Y Avg)-119113.09%

Cash / Share (Quarterly)$0.06

Revenue Growth QoQ (YoY)54.23%

ROA (Last FY)-155.91%

Revenue Growth TTM (YoY)-42.43%

EBITD / Share (TTM)$-0.20

ROE (5Y Avg)-119.32%

Operating Margin (TTM)-1112.87%

Cash Flow / Share (Annual)$-0.18

P/B Ratio180.98x

P/B Ratio (Quarterly)144.09x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)120.97x

Net Interest Coverage (TTM)-14.90x

ROA (TTM)-99.22%

EPS Incl Extra (Annual)$-0.23

Current Ratio (Annual)1.06x

Quick Ratio (Quarterly)0.81x

3-Month Avg Trading Volume6.85M

52-Week Price Return190.61%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$45.33

P/S Ratio (Annual)144.89x

Asset Turnover (Annual)0.10x

52-Week High$2.73

Operating Margin (5Y Avg)-45112.35%

EPS Excl Extra (Annual)$-0.23

CapEx CAGR (5Y)-9.81%

26-Week Price Return8.94%

Quick Ratio (Annual)0.81x

13-Week Price Return9.55%

Total Debt / Equity (Annual)0.97x

Current Ratio (Quarterly)1.06x

Enterprise Value$649.621

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)-13.42%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1537.41%

Cash / Share (Annual)$0.06

3-Month Return Std Dev107.77%

Net Income / Employee (TTM)$-1

ROE (Last FY)-182.42%

Net Interest Coverage (Annual)-15.28x

EPS Basic Excl Extra (Annual)$-0.23

Total Debt / Equity (Quarterly)8.04x

EPS Incl Extra (TTM)$-0.22

ROI (TTM)-155.30%

P/S Ratio (TTM)119.07x

Pretax Margin (5Y Avg)-63113.09%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$45.33

Price vs S&P 500 (52W)160.78%

Year-to-Date Return44.44%

5-Day Price Return4.28%

EPS Normalized (Annual)$-0.23

ROA (5Y Avg)-89.86%

Net Profit Margin (Annual)-1537.41%

Month-to-Date Return7.73%

Cash Flow / Share (TTM)$-0.32

EBITD / Share (Annual)$-0.20

Operating Margin (Annual)-1425.70%

LT Debt / Equity (Annual)0.92x

ROI (5Y Avg)-96.85%

LT Debt / Equity (Quarterly)8.04x

EPS Basic Excl Extra (TTM)$-0.22

P/TBV (Quarterly)1.94x

P/B Ratio (Annual)7.91x

Pretax Margin (TTM)-1192.18%

Book Value / Share (Annual)$0.10

Price vs S&P 500 (13W)8.86%

Beta2.45x

Revenue / Share (TTM)$0.02

ROE (TTM)-491.22%

52-Week Low$0.64

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.09

4.15

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
OCGNOcugen, Inc. Common Stock	119.07x	-42.43%	—	—	$1.93
AMGNAmgen Inc	5.13x	9.95%	73.30%	2.93%	$349.39
GILDGilead Sciences Inc	5.84x	2.40%	78.83%	133.64%	$138.55
ARGXargenx SE American Depositary Shares	12.46x	89.56%	150.91%	—	$828.35
BNTXBioNTech SE American Depositary Share	8.75x	-11.81%	84.21%	—	$102.12
BIIBBiogen Inc. Common Stock	2.60x	2.22%	75.69%	-18.77%	$176.02
MRNAModerna, Inc. Common Stock	11.02x	-39.93%	70.32%	—	$54.68
NBIXNeurocrine Biosciences Inc	4.49x	21.45%	98.18%	2.31%	$128.41
EXELExelixis Inc	4.96x	6.85%	96.39%	31.10%	$44.38
TECHBio-Techne Corp.	7.60x	1.64%	66.60%	-20.58%	$57.36
HALOHalozyme Therapeutics, Inc.	5.74x	37.55%	83.62%	22.89%	$66.64

About

Ocugen Inc develops gene therapies, cell therapies, and vaccines targeting unmet medical needs across multiple therapeutic areas. The company's primary focus is on retinal diseases, including inherited conditions such as retinitis pigmentosa and Leber congenital amaurosis, as well as age-related diseases including dry age-related macular degeneration and geographic atrophy. Its pipeline includes modifier gene therapy, novel biologics, regenerative medicine cell therapies, and inhaled mucosal vaccine platforms.